(Q37565638)

21 August 2017

1 reference

title

Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence (English)

1 reference

21 August 2017

3

Jean-Yves Reginster

1 reference

21 August 2017

Véronique Rabenda

1

1 reference

21 August 2017

Michaël Hiligsmann

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

Expert Opinion on Pharmacotherapy

21 August 2017

published in

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

14

1 reference

21 August 2017

page(s)

2303-2315

1 reference

An estimate of the worldwide prevalence and disability associated with osteoporotic fractures

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

A model of lifetime osteoporosis impact.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

A model of osteoporosis impact in Switzerland 2000-2020.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Low Frequency of Treatment of Osteoporosis Among Postmenopausal Women Following a Fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Undertreatment with anti-osteoporotic drugs after hospitalization for fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Low incidence of anti-osteoporosis treatment after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Persistence with weekly alendronate therapy among postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Loss of treatment benefit due to low compliance with bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Compliance with pharmacologic therapy for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Compliance with drug therapies for the treatment and prevention of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Early discontinuation of treatment for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Determinants of adherence to osteoporosis treatment in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Compliance with osteoporosis medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

The impact of compliance with osteoporosis therapy on fracture rates in actual practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

A meta-analysis of the association between adherence to drug therapy and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Assessment of compliance with osteoporosis treatment and its consequences in a managed care population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903140533

10.1517/14656560903140533

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference